Clinic Software← All companies
ResVita Bio
therapeutics company dedicated to developing life-changing treatments for skin diseases
StageSeed/Grant-funded
Raised$2.5M
Founded2021
Employees9
LocationBerkeley, CA
About
The physical and emotional challenges of chronic skin diseases are devastating to patients, particularly children. ResVita Bio seeks to restore and maintain the vitality of the skin through engineered skin probiotics. Through synthetic biology and metabolic engineering, we are developing a safe and versatile skin microbial platform that continuously deliver therapies that address the causes of chronic skin diseases. ResVita Bio is developing a rich product pipeline to treat inflammatory skin diseases like Netherton Syndrome, atopic dermatitis, psoriasis, acne, and rosacea.
Product
- Value proposition
- Engineered bacteria deliver continuous, local therapeutic proteins to affected skin areas, enabling sustained treatments with topical convenience and minimized systemic side effects.
Founders
- Amin Zargar — CEO and co-founder
- Jay Keasling — Co-founder and Board Member
Products
continuous protein therapy platformtopical therapeutic proteins delivery system
Key features
engineered bacteria as living factoriescontinuous protein therapy delivering sustained treatmentstopical, once-daily applicationability to deliver multiple therapies in a single treatmentminimized systemic side effects
Technologies
genetically engineered bacteriamicrobial therapeuticsprotein designmachine learning–guided protein design
Target conditions
Netherton SyndromeAtopic Dermatitiseczemaskin diseases
Traction metrics
20 (unspecified)
Investors
National Institute of Arthritis and Musculoskeletal and Skin Diseases (part of NIH)US Department of Health and Human Services (HHS)Berkeley Frontier FundGaingelsJeffrey KimPioneer Fund
News
- ResVita Bio Announces Positive FDA Pre-IND Meeting, Advancing RVB-003 Toward IND Filing for Netherton Syndrome in Early 2026 · 2025-09-24T13:31:00.000Z
- ResVita Bio's founder designed experiments to kill his own startup... · 2025-07-08T00:00:00.000Z
- Resvita Biosciences | Intellectual Property & Industry Research... · 2025-09-24T00:00:00.000Z
- ResVita Bio Announces RVB-003 granted Orphan Drug Designation for Netherton Syndrome by the FDA · 2025-04-03T12:47:00.000Z
- ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors · 2026-06-09T12:43:00.000Z
- National Institutes of Health (NIH) Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome · 2024-09-24T12:40:00.000Z
